Literature DB >> 34313883

Circular RNA circ_0001017 Sensitizes Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy by the miR-543/PHLPP2 Axis.

Jianmin Zhang1,2, Wenzhang Zha2, Changchun Qian2, Aixing Ding2, Zhongqi Mao3.   

Abstract

Resistance to cisplatin (CDDP) remains a major challenge for the treatment of gastric cancer (GC). Circular RNAs (circRNAs) have been implicated in the development of CDDP resistance of GC. However, the precise actions of circ_0001017 in CDDP resistance of GC remain to be elucidated. The levels of circ_0001017, microRNA (miR)-543 and PH-domain and leucine-rich repeat protein phosphatase 2 (PHLPP2) mRNA were gauged by quantitative real-time polymerase chain reaction (qRT-PCR). Western blot was used to analyze the protein levels of Vimentin, N-cadherin, E-cadherin, and PHLPP2. Ribonuclease R (RNase R) assay was applied to evaluate the stability of circ_0001017. Cell viability and proliferation, colony formation ability, cell cycle distribution and apoptosis, and migration and invasion were detected by the Cell Counting Kit-8 (CCK-8), colony formation, flow cytometry, and transwell assays, respectively. Direct relationship between miR-543 and circ_0001017 or PHLPP2 was verified by dual-luciferase reporter and RNA immunoprecipitation (RIP) assays. Xenograft model assay was used to assess the function of circ_0001017 in vivo. Low expression of circ_0001017 was associated with CDDP resistance of GC. Enforced expression of circ_0001017 impeded growth, metastasis, and enhanced apoptosis of HGC-27/R and AGS/R cells and sensitized them to CDDP in vitro. Circ_0001017 targeted miR-543, and circ_0001017 regulated CDDP-resistant cell behaviors and CDDP sensitivity by suppressing miR-543. PHLPP2 was a direct target of miR-543, and circ_0001017 controlled PHLPP2 expression through miR-543. Moreover, miR-543 knockdown-mediated promotion of PHLPP2 impacted CDDP-resistant cell behaviors and CDDP sensitivity in vitro. Additionally, elevated expression of circ_0001017 hindered growth of HGC-27/R cells and sensitized them to CDDP in vivo. Our findings demonstrated that enforced expression of circ_0001017 suppressed malignant behaviors and enhanced CDDP sensitivity of CDDP-resistant GC cells at least partially by the miR-543/PHLPP2 axis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CDDP resistance; Gastric cancer; PHLPP2; circ_0001017; miR-543

Mesh:

Substances:

Year:  2021        PMID: 34313883     DOI: 10.1007/s10528-021-10110-6

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  2 in total

Review 1.  The role of chemotherapy in metastatic gastric cancer.

Authors:  Felice Pasini; Anna Paola Fraccon; Giovanni DE Manzoni
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

2.  LncRNA Expression Profiling in Advanced Resected Gastric Adenocarcinoma Tissues.

Authors:  Yuan Dang; Liying Lin; Xiaojuan Ouyang; Fan Zhang; Shaoquan Chen; Bing Wang; Zaizhong Zhang; Shuming Chen; Lin Deng; Wen Wang; Lie Wang; Chunhong Xiao; Yafeng Qi
Journal:  Clin Lab       Date:  2019-12-01       Impact factor: 1.138

  2 in total
  4 in total

Review 1.  Prospects of circular RNAs: the regulators of drug resistance and metastasis in gastric cancer.

Authors:  Bingyu Wang; Zihao Chen; Wenbo Liu; Bibo Tan
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

Review 2.  The Role of Circular RNAs in the Drug Resistance of Cancers.

Authors:  Xin-Yuan Liu; Qi Zhang; Jing Guo; Peng Zhang; Hua Liu; Zi-Bin Tian; Cui-Ping Zhang; Xiao-Yu Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

3.  Hsa_circ_0001017 promotes cell proliferation, migration and invasion in osteosarcoma by sponging miR-145-5p.

Authors:  Qinglei Yang; Hongying Yu; Konghe Hu
Journal:  J Orthop Surg Res       Date:  2022-03-28       Impact factor: 2.359

Review 4.  Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications.

Authors:  Xuehao Zhou; Xiang Ao; Zhaojun Jia; Yiwen Li; Shouxiang Kuang; Chengcheng Du; Jinyu Zhang; Jianxun Wang; Ying Liu
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.